Free tool
FAERS Monitor: Gastrocrom
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020479 or its brand name (Gastrocrom, Cromolyn Sodium). Reports on generic versions are filed under their own applications.
Reports
3,311
Serious
1,201
36% of reports
Hospitalization
381
Death reported
38
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- treatment failure1,006
- drug ineffective301
- fatigue204
- nausea193
- headache168
- off label use164
- diarrhoea160
- urticaria147
- dyspnoea130
- anaphylactic reaction127
- pruritus124
- pain122
- hypersensitivity114
- malaise110
- condition aggravated109
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 28 |
| 2005 | 24 |
| 2006 | 17 |
| 2007 | 20 |
| 2008 | 28 |
| 2009 | 44 |
| 2010 | 39 |
| 2011 | 45 |
| 2012 | 26 |
| 2013 | 16 |
| 2014 | 25 |
| 2015 | 40 |
| 2016 | 85 |
| 2017 | 65 |
| 2018 | 70 |
| 2019 | 104 |
| 2020 | 1,101 |
| 2021 | 139 |
| 2022 | 212 |
| 2023 | 256 |
| 2024 | 317 |
| 2025 | 346 |
| 2026 | 264 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,848 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| treatment failureSignal | 1,006 | 78.1 | 74.1 | 75,838 |
| anaphylactic reactionSignal | 127 | 14.6 | 12.3 | 1,600 |
| urticariaSignal | 147 | 5.6 | 4.8 | 552 |
| hypersensitivitySignal | 114 | 3.9 | 3.3 | 245 |
| condition aggravatedSignal | 109 | 2.3 | 1.9 | 78 |
| pruritusSignal | 124 | 2.1 | 1.7 | 67 |
| headache | 168 | 1.7 | 1.5 | 49 |
| fatigue | 204 | 1.7 | 1.5 | 56 |
| malaise | 110 | 1.6 | 1.3 | 24 |
| diarrhoea | 160 | 1.6 | 1.4 | 34 |
| nausea | 193 | 1.5 | 1.4 | 38 |
| dyspnoea | 130 | 1.5 | 1.2 | 19 |
| drug ineffective | 301 | 1.5 | 1.3 | 45 |
| pain | 122 | 1.3 | 1.1 | 7 |
| off label use | 164 | 1.2 | 1.0 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.